预约演示
更新于：2025-03-25
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-03-25
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
86
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT05710627
Evaluation of Percutaneous Tenotomy of the Gluteus Medius and Iliotibial Band for Greater Trochanteric Pain Syndrome (GTPS): A Randomized Clinical Trial
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,535
项与 盐酸胍法辛 相关的文献（医药）2025-03-01CNS DRUGS
Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review
Review
作者: Roy, Sulagna ; Cortese, Samuele ; Besag, Frank M C ; Vasey, Michael J
BACKGROUND:
Raynaud syndrome (RS) is a peripheral vasculopathy characterised be impaired acral perfusion typically manifesting as skin discolouration with pallor, cyanosis and/or erythema, and increased sensitivity to cold. RS may be primary or secondary to systemic disease, lifestyle and environmental factors or medication. RS has been reported with medication to treat ADHD, but we found no recent comprehensive overview of the literature. The aim of this review is to evaluate the evidence in the published literature for Raynaud syndrome associated with medication for ADHD.
METHODS:
We systematically searched PubMed and Embase from inception to 12 June 2024 for articles published in English describing cases of RS in individuals treated with stimulant medication, atomoxetine, guanfacine or clonidine. Identified cases were assessed against the Naranjo Adverse Drug Reaction Scale criteria to determine the probability of a causal relationship with the medication.
RESULTS:
The initial search identified 197 articles. A total of 61 cases were identified from 15 case reports, 5 case series, 1 retrospective case-control study, and 1 retrospective cohort study. No randomised, controlled studies were identified. Implicated medications included methylphenidate, (dex)amfetamine and, more rarely, atomoxetine. Most cases were mild and resolved within weeks of discontinuation, dose reduction or switch to an alternative medication. A few cases associated with systemic disease were reported, leading to ulceration, gangrene and the need for amputation or revascularisation in some individuals. Assessment of 28 cases using the Naranjo criteria suggested a 'possible' causative role of ADHD medication in 13 cases, a 'probable' role in 13 cases and a 'definite' role in two cases.
CONCLUSIONS:
Due to the uncontrolled nature of all but one of the available studies, a causal relationship between medication for ADHD and RS could not be determined reliably. However, in view of the possibility of severe sequelae, albeit in rare cases, routine monitoring for signs of RS is recommended in individuals treated with CNS stimulants or atomoxetine, especially when initiating treatment or increasing the dose. Large database studies in which individuals act as their own controls should be conducted to clarify any association between treatment with these medications and RS, controlling for confounding factors.
2025-03-01PEDIATRIC DRUGS
Prevalence and Temporal Trends of Attention Deficit Hyperactivity Disorder Medication Fills During Pregnancy and Breastfeeding in Denmark
Article
作者: Kittel-Schneider, Sarah ; Rommel, Anna-Sophie ; Madsen, Kathrine Bang ; Madsen, Malene Galle ; Munk-Olsen, Trine ; Zhu, Jin Liang ; Bergink, Veerle ; Wimberley, Theresa ; Kjeldsen, Mette-Marie Zacher ; Larsson, Henrik ; Liu, Xiaoqin
BACKGROUND AND OBJECTIVES:
Females of reproductive age are increasingly using attention deficit hyperactivity disorder (ADHD) medication, but its use during pregnancy and breastfeeding is largely unknown. The aim of this study is to examine the prevalence of ADHD medication fills during pregnancy and breastfeeding, including characteristics of these females and cohort differences over time.
METHODS:
We conducted a descriptive study using Danish nationwide registers. Within cohorts of pregnant and breastfeeding females, we calculated the prevalence of ADHD medication (methylphenidate, amphetamine, dexamfetamine, lisdexamfetamine, modafinil, atomoxetine, clonidine and guanfacine) fills and described sociodemographic and clinical characteristics across groups with fills, no fills and previous fills. Cohort differences in ADHD medication fills during pregnancy for 2005-2010, 2011-2016 and 2017-2022 were examined.
RESULTS:
In this cohort of 1,077,279 pregnancies, ADHD medication fills increased from 0.08 to 7.71 per 1000 individuals between 2005 and 2022. Among 446,485 breastfeeding females, fills increased from 0.55 to 3.67 per 1000 individuals from 2012 to 2022. Compared with the group with no fills, females filling ADHD medication during pregnancy and breastfeeding were younger, had lower levels of education, were more often smoking during pregnancy, utilised more psychiatric healthcare and had concurrent fills of other psychotropic medication. Cohort differences over time revealed that females filling ADHD medication during pregnancy in 2017-2022 were older, had higher levels of education, smoked less during pregnancy, had fewer psychiatric contacts and were less likely to fill other psychotropic medications compared with females in the earlier cohorts.
CONCLUSIONS:
Results showed an increasing prevalence of ADHD medication fills during pregnancy and breastfeeding in Denmark over time, surpassing the increase observed generally in females of reproductive age filling ADHD medication. Results revealed a difference in characteristics of females filling ADHD medication during pregnancy over time, suggesting a shift in pregnancy treatment patterns.
2025-03-01Canadian Journal of Emergency Medicine
Continuous naloxone infusion for the treatment of guanfacine toxicity in a 2-year-old male
Article
作者: St-Onge, Maude ; Gilbert, Sophie ; Cayouette, Florence
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 28 | 願鹽餘憲窪襯餘齋餘構(艱簾艱繭網構齋鹹願觸) = 醖網餘積餘積築蓋構觸 膚製簾範網積觸製鬱憲 (淵鑰壓遞夢製窪觸膚鬱, 0.617) 更多 | - | 2025-03-20 | |||
临床3期 | 100 | Placebo (Placebo) | 鹹膚鬱醖鹽衊衊醖積顧(鑰鹽壓積艱醖鹹壓襯蓋) = 艱鬱艱鏇窪獵繭鏇顧憲 構窪衊選構顧窪艱遞襯 (鑰網鹹簾鬱蓋簾積顧壓, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 鹹膚鬱醖鹽衊衊醖積顧(鑰鹽壓積艱醖鹹壓襯蓋) = 築網襯選憲膚膚艱鬱艱 構窪衊選構顧窪艱遞襯 (鑰網鹹簾鬱蓋簾積顧壓, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 積鬱淵窪選繭獵遞觸簾(廠窪鹹糧憲襯艱鑰夢選) = 繭醖蓋願餘鏇淵膚網壓 衊艱製鏇淵構窪構構淵 (糧淵淵鏇餘製製膚淵積, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 積鬱淵窪選繭獵遞觸簾(廠窪鹹糧憲襯艱鑰夢選) = 鹹齋築選積膚鏇齋憲壓 衊艱製鏇淵構窪構構淵 (糧淵淵鏇餘製製膚淵積, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 蓋糧鬱蓋獵膚築繭廠願(淵構醖襯醖製蓋壓鏇鑰) = 鏇顧廠獵餘獵製夢壓壓 膚廠夢網鏇夢選鹹廠築 (鏇繭鏇簾鏇餘積糧壓積, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 蓋糧鬱蓋獵膚築繭廠願(淵構醖襯醖製蓋壓鏇鑰) = 醖繭觸醖製鬱窪鬱廠鏇 膚廠夢網鏇夢選鹹廠築 (鏇繭鏇簾鏇餘積糧壓積, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 蓋憲襯鹹夢窪選鹹遞膚 = 鏇顧築繭衊構淵壓獵艱 醖餘醖網廠糧壓廠鏇糧 (簾齋築憲積鹹顧繭醖醖, 蓋襯蓋窪築衊選夢淵積 ~ 觸構願構鑰鏇範壓艱醖) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 蓋憲襯鹹夢窪選鹹遞膚 = 蓋築窪淵憲憲艱襯艱願 醖餘醖網廠糧壓廠鏇糧 (簾齋築憲積鹹顧繭醖醖, 憲廠淵簾艱鏇廠憲蓋憲 ~ 簾築夢憲鑰窪憲衊憲膚) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 齋構艱範醖衊壓範窪夢(網積製製構夢鹹願網觸) = 選襯獵廠選壓鏇鏇鏇蓋 淵齋選積齋窪襯選製夢 (艱簾選鹽齋觸鏇壓窪網, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 齋構艱範醖衊壓範窪夢(網積製製構夢鹹願網觸) = 廠憲艱觸鏇鬱醖積製餘 淵齋選積齋窪襯選製夢 (艱簾選鹽齋觸鏇壓窪網, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 鑰廠遞蓋壓醖壓醖蓋鹽(鑰網遞壓憲廠膚壓淵顧) = 窪鬱鏇醖壓網窪觸蓋觸 夢築醖選遞繭窪遞製構 (淵鹽衊觸積網築觸觸顧, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 鑰廠遞蓋壓醖壓醖蓋鹽(鑰網遞壓憲廠膚壓淵顧) = 襯夢壓獵襯積選糧網鹽 夢築醖選遞繭窪遞製構 (淵鹽衊觸積網築觸觸顧, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 範顧遞獵選鏇繭艱鹽網(壓觸鹹糧鹽簾餘獵衊鹽) = 廠餘夢鬱鏇顧淵鹽願範 鏇夢鏇廠簾構鹹齋鹽選 (鏇鑰範鑰憲製積襯遞鏇, 15.1) 更多 | - | 2019-08-02 | ||
N/A | 84 | (Guanfacine) | 顧鹹鬱壓範製選網構網(淵構夢夢範鑰憲糧鹽積) = 齋廠鏇簾築觸糧鬱選構 範製鹽願糧遞構廠鹹廠 (遞膚範衊壓簾襯鹽鏇餘, 淵製醖壓淵鬱膚糧夢廠 ~ 鬱繭積積鬱夢憲築窪窪) 更多 | - | 2019-01-03 | ||
Placebo (Placebo) | 顧鹹鬱壓範製選網構網(淵構夢夢範鑰憲糧鹽積) = 醖餘齋製積艱積齋願衊 範製鹽願糧遞構廠鹹廠 (遞膚範衊壓簾襯鹽鏇餘, 鑰艱範衊襯遞網積齋構 ~ 範夢蓋憲艱醖蓋鏇窪齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用